When Should We Use a New DES ? Dr R H Stables Cardiothoracic Centre Liverpool UK.

Slides:

Advertisements

Similar presentations

A Prospective, Randomized Comparison of Paclitaxel-eluting TAXUS Stents vs. Bare Metal Stents During Primary Angioplasty in Acute Myocardial Infarction.

Advertisements

The value of DES in unprotected left main lesions has not been evaluated by dedicated randomized clinical trials. Especially, it is not known whether currently.

Single-Patient Use of Investigational Drugs and Biologic Products for Treating Cancer Grant Williams, M.D. Medical Team Leader DODP/CDER/FDA.

SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents Christoph Varenhorst M.D Ph.D;

Four Drug Eluting Stent Trials Keith D Dawkins MD FRCP FACC Southampton University Hospital Keith D Dawkins MD FRCP FACC Southampton University Hospital.

Coronary Revascularisation in Patients With Diabetes Mellitus Dr Rod Stables The Cardiothoracic Centre Liverpool UK.

Angioplasty’s Fight against Restenosis: Drug Eluting Stents & Bare Metal Stents.

Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer

Stages of drug development

AHRQ’s Role in Comparative Effectiveness Carolyn M. Clancy, MD Director Agency for Healthcare Research and Quality Alliance for Health Reform Briefing.

 Be familiar with the types of research study designs  Be aware of the advantages, disadvantages, and uses of the various research design types  Recognize.

Figure 4.1 NEW PRODUCT DEVELOPMENT PROCESS Finance Corporate strategy and portfolio decisions Regulatory affairs Marketing and sales + market research.

Yesterday, today, and tomorrow

“Randomised trials of CABG v PCI are no longer possible and cannot represent real life practice.” Dr Rod Stables The Cardiothoracic Centre Liverpool UK.

Chapter 1.3.  Sell 1 group of similar products.  Ex. The protocols for manufacturing recombinant human growth hormone are almost identical to those.

Regulatory Problems Moderators: Eugene Chen and Michael Kochman, MD.

1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.

DR ALEX CHASE REGIONAL HEART CENTRE MORRISTON SWANSEA SLIDE MATERIAL:PERSONAL COMMUNICATION WITH AUTHORS ABBOTT, BOSTON SCIENTIFIC, CORDIS, MEDTRONIC TCT.

Stent or Surgery: What is Best for a Woman ? Dr R H Stables Cardiothoracic Centre Liverpool UK.

Dietary Supplements. Definition by DSHEA Product that is to supplement a healthy diet. Includes ingredients such as vitamins, minerals, herbs, botanicals,

Summary: Biological Therapeutics for Rare Plasma Protein Disorders Workshop July 21, 2005 Mark Weinstein, Ph.D. Office of Blood Research and Review CBER,

Key Compliance Risks in Clinical Trials Kathleen Meriwether Principal, ERNST & YOUNG, LLP Fraud Investigation & Dispute Services.

The Use of Scientific Advisory Boards An Invaluable Tool in Drug Development Dr Robert Miller Chief Medical Officer Fulcrum Pharma Developments 19 th Annual.

HORIZONS AMI Trial H armonizing O utcomes with R evascular IZ ati ON and S tents In A cute M ycoardial I nfarction H armonizing O utcomes with R evascular.

DEVELOPING EVIDENCE ON VACCINE SAFETY Susan S. Ellenberg, Ph.D. Center for Clinical Epidemiology and Biostatistics U Penn School of Medicine Global Vaccines.

Disclosures The presenter has no financial involvement with the product or competing products being discussed. The presenter received travel and lodging.

Innovation and Merger Control: M Johnson & Johnson - Guidant Benoit Durand Director of Economic Analysis 24 November 2006 BIICL.

Top Trial Cheats Dr Rod Stables The Cardiothoracic Centre Liverpool UK No Conflicts of Interest to Declare.

Unresolved issues with Drug-eluting Stents Stent Thrombosis Advanced Angioplasty 2007 Dan Blackman Yorkshire Heart Centre.

TAXUS Landmark Analysis Impact of Long-Term Clopidogrel Usage on Death, Myocardial Infarction and Stent Thrombosis Gregg W. Stone, MD Stephen G. Ellis,

Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.

Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress 1 How to Implement a Private Payer Reimbursement Strategy Barbara Grenell.

1 Operation of the Prescription Drug User Fee Program Janet Woodcock, M.D. Deputy Commissioner for Operations November 14, 2005.

Late loss in the choice of DES: Monty Python or the Holy Grail? Azfar Zaman Freeman Hospital, Newcastle-upon-Tyne.

PCI v CABG Dr Rod Stables The Cardiothoracic Centre Liverpool UK.

GenCo Sam Rana 12/16/13.

Biosimilars are effective and safe and should immediately replace innovator molecules in the NHS Dr Chris Deighton Consultant Rheumatologist.

Process mapping of registration to reimbursement for new pharmaceuticals in UK.

Critical Path Initiative Sousan S. Altaie, Ph.D. Scientific Policy Advisor OIVD/CDRH.

1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.

M. Valgimigli, MD, PhD University of Ferrara, ITALY On behalf of the PRODIGY Investigators PROlonging Dual antiplatelet treatment after Grading stent-induced.

Balancing revenues and costs for orphan drugs: a case study Aidan Hollis University of Calgary: Department of Economics and O’Brien Institute of Public.

Clinical Trials and You Ellen Valentine, M.S., CCC-SLP Community Outreach and Education Program Science Park Research Division, Smithville, Texas.

November 9, 2015 February 20, 2017 Using real world evidence – industry perspective Pma indication expansion Melissa hasenbank, phd Sr. Clinical Research.

Leveraging Bayesian Methodology to Increase the Trial Efficiency

Dental Standards & Testing Methods

INFRATIBIAL INTERVENTIONS Current Results with DES

Is High Placebo Response Really a Problem in Clinical Trials?

OUS Data: What does the CE Mark Really Mean?

Premarket Notification 510(k) process

Industry Perspective: Expanded Access Programs

First-in-Man, First In The USA: What’s The Difference?

Deputy Director, Division of Biostatistics No Conflict of Interest

On behalf of all principal COMPARE II investigators:

Figure 1 Principal degradation characteristics of CE-marked bioresorbable scaffolds. For each device data are shown, where available, for radial support.

Benefits of US EFS: A Clinical Perspective

The FDA’s View on CTO-PCI Devices

Are we using fewer Covered Stents for SFA Occlusive Disease?

How (Much) Should We Pay for TAVI?

Is a Clinical Trial Right for Me?

The STENT Thrombosis Study

REALITY: 8 month results

Biosimilars in Hematologic Oncology

Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.

Suzanne M. Sensabaugh, MS, MBA

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.

Process mapping of registration to reimbursement for new pharmaceuticals in UK Description: A systematic methodology was developed in order to create the.

Structures of Central Banks and the Federal Reserve System

Drug-eluting coronary stent market overview

Presentation transcript:

When Should We Use a New DES ? Dr R H Stables Cardiothoracic Centre Liverpool UK

Conflict of Interest UK or European advisory boards Boston Scientific, Cordis, Medtronic Educational grants or lecture fees Boston Scientific, Cordis, Medtronic, Guidant Research grants or paid role as trial PI Cordis, Boston Scientific, Medtronic, Biocompat Share holding or other financial interest None

What is a New DES ? Established DES Cypher Taxus Characterised DES Endeavour Emerging DES eg Co-Star Xience Developmental DES Pseudo DES

Some Facts About DES Technology Difficult to create a safe and efficacious DES Pre-clinical - stage advance hit rate 150:1 Clinical products - fail : success ratio = 4 History of DES product at GUIDANT DES abandoned after launch ZoMax - most recent Similar (identical) drug or components - no guide CE mark - no proof of product efficacy The cautionary tale of the Sorin Janus DES …..

The Sorin ‘Janus’ Story CE mark approved DES sold in the UK Typical DES pricing Limited registry type data ‘Plausible’ design - presented as an advance

The Sorin ‘Janus’ Story CE mark approved DES sold in the UK Typical DES pricing Limited registry type data ‘Plausible’ design - presented as an advance Implanted in patients with DES indications At UK taxpayers’ expense At whim of UK cardiologists Subsequent RCT - Equivalent to its own control - Carbostent

Why Use a New DES ? Formal, quality RCT evaluation of a new DES Performance advantage Handling and deliverability Safety or efficacy? - not proven at this stage Cost advantage Direct (unit) cost Market impact - critical number of competitors Supply and availability Treat more lesions with DES ?

But Don’t be Fooled by These…. Its seems new and exciting … I could be one of the first to use it I am just giving it a try …… You cannot ‘try’ the drug eluting part of a DES The components (drug) work in other stents The design has clear, self evident advantages … I am part of a research project ‘Mickey Mouse’ registry - marketing exercise

Taking the Plunge Critical mass of data on safety and efficacy Portfolio of research projects At least one powered RCT against standard Angiographic follow-up and analysis Clinical outcomes beyond one year Continued commitment to research and outcome analysis More FDA than CE mark standard

Questions and Discussion